Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LB2102 |
Trade Name | |
Synonyms | LB-2102|LB 2102 |
Drug Descriptions |
LB2102 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting DLL3, which potentially induce toxicity in DLL3-expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C199628 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
LB2102 | LB2102 | 0 | 1 |